CA
NZ
UK
AU
IND
US
Heartflow (NASDAQ:HTFL) shares traded up 8.27% to $55.24, near a 52-week high of $55.46, as investors responded to Piper Sandler raising its price target to $64 from $45 while keeping an Overweight rating. The firm cited the company's competitive moat.
Omada Health (NASDAQ:OMDA) shares traded up 6.36% to $19.21 after the company announced it will present peer-reviewed research at the World Obesity and Weight Management Congress in Boston. The findings were published in the journal Diabetes, Obesity and Metabolism.
SCWorx (NASDAQ:WORX) shares traded up 44.40% to $3.87 after the company announced a new agreement with an independent, community-owned healthcare system serving New Mexico, Arizona, Colorado and Utah. Under the deal, SCWorx will provide healthcare supply chain data management services to improve the accuracy, …
Tempus AI (NASDAQ:TEM) shares traded up 6.98% to $68.83 after the company announced results from a study of an AI-enabled pre-screening panel for advanced non-small cell lung cancer. The panel reached greater than 80% sensitivity across all 12 biomarkers assessed and above 90% for …
The approved protocol update allows Alvotech (NASDAQ: ALVO) to extract significantly more drug substance from each production run of SIMLANDI, the company’s biosimilar referencing Humira (adalimumab), a widely used anti-inflammatory biologic historically prescribed for conditions including rheumatoid arthritis, psoriasis and inflammatory bowel disease. By …
The filing leans on neurofilament light chain (NfL) data, a blood-based biomarker that reflects the degree of neuronal and axonal damage occurring in neurodegenerative disease. Regulators have increasingly accepted NfL as a surrogate marker capable of supporting accelerated-approval pathways in conditions such as ALS, …
ProSense is IceCure Medical’s (NASDAQ: ICCM) minimally invasive cryoablation system, which destroys targeted tissue using extreme cold rather than surgical excision, and has already received FDA clearance for use in appropriate low-risk breast cancer cases. The ChoICE study is structured as a post-market registry …
The FDA’s Orphan Products Development grant program funds clinical studies of products intended to treat rare diseases and conditions, and the award to Marker Therapeutics (NASDAQ: MRKR) will support the costs associated with advancing MT-601 into a dedicated Phase 1 study in pancreatic cancer, …
Netherton syndrome is a rare autosomal recessive skin disorder caused by mutations in the SPINK5 gene, typically presenting with widespread skin inflammation, impaired skin barrier function, and chronic itching that can severely affect quality of life from early childhood. The published case, conducted under …
The study enrolled 253 adults diagnosed with acute manic or mixed episodes associated with bipolar I disorder. By Week 3 of treatment, patients receiving RAP-219 showed a 3.1-point placebo-adjusted reduction on the Young Mania Rating Scale (YMRS), the standard clinician-rated measure of manic symptom …
Please wait processing your request...